Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
Rhea-AI Summary
Vaxcyte (Nasdaq: PCVX) management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in New York on Thursday, February 12, 2026 at 1:30 p.m. ET / 10:30 a.m. PT.
A live webcast will be available via the company Investor site and a replay will be accessible for approximately 30 days after the conference.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
While PCVX was down 0.81%, several biotech peers also traded lower, including ACAD (-2.38%), ARWR (-4.32%), ACLX (-0.95%), KRYS (-4.33%) and MTSR (-0.34%). The momentum scanner did not flag this as a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 02 | Equity offering closing | Negative | -2.9% | Closed underwritten public offering raising $632.5M gross at $50 per share. |
| Jan 29 | Offering priced | Negative | +2.8% | Priced $550M underwritten common stock offering at $50 per share. |
| Jan 29 | Offering launch | Negative | +2.8% | Announced proposed $500M common stock and pre-funded warrant offering. |
| Jan 22 | Pipeline advancement | Positive | +7.2% | Advanced adult and infant VAX-31 programs and outlined Phase 3 timelines. |
| Dec 08 | Phase 3 trial start | Positive | -0.7% | Dosed first participants in pivotal OPUS Phase 3 trial of VAX-31 in adults. |
Recent offerings often saw mixed reactions, while major clinical and pipeline updates produced stronger, sometimes positive, moves with occasional divergences.
Over recent months, Vaxcyte combined major financing activity with advancement of its VAX-31 programs. In Jan 2026, it announced and priced sizable equity offerings, followed by closing a $632.5 million deal on Feb 2, 2026. Earlier, it reported Phase 3 progress and manufacturing build-out plans for VAX-31 and began dosing in a pivotal Phase 3 trial in Dec 2025. Today’s conference appearance fits within an active communication and development period.
Market Pulse Summary
This announcement highlights non‑dilutive, visibility‑oriented news: a fireside chat at a Guggenheim biotech summit scheduled for February 12, 2026. It follows a period of significant capital raises and major VAX-31 development milestones, supported by a cash position of $2.67 billion as of late 2025. Investors tracking the story may focus on updates around Phase 3 timelines, spending levels, and how management frames its long-term strategy at such events.
AI-generated analysis. Not financial advice.
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in New York on Thursday, February 12, 2026 at 1:30 p.m. ET / 10:30 a.m. PT.
A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in a Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise.
Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com.
Contacts:
Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com
Jeff Macdonald, Executive Director, Investor Relations
Vaxcyte, Inc.
917-371-0940
investors@vaxcyte.com
FAQ
When will Vaxcyte (PCVX) present at the Guggenheim Emerging Outlook: Biotech Summit?
How can investors watch the Vaxcyte (PCVX) fireside chat webcast?
Will Vaxcyte (PCVX) make a replay of the Guggenheim fireside chat available?
What topics might Vaxcyte (PCVX) cover during the Guggenheim fireside chat on February 12, 2026?
Where is the Guggenheim Emerging Outlook: Biotech Summit taking place for the Vaxcyte (PCVX) presentation?
